Arbutus Biopharma
ABUSABUS · Stock Price
Historical price data
Overview
Arbutus Biopharma is a pure-play virology company with a mission to achieve a functional cure for chronic hepatitis B (HBV). Its core strategy is a multi-mechanistic combination approach, anchored by its RNAi therapeutic imdusiran, which has demonstrated meaningful functional cure rates in clinical trials. The company is led by a newly appointed, transaction-savvy leadership team with deep expertise in building and scaling biotech ventures. Arbutus's concentrated focus on the large, underserved HBV market positions it as a key contender in the race for a curative regimen.
Technology Platform
A proprietary three-pillar combination therapy framework ('Suppress, Reduce, Boost') for HBV, integrating RNAi for antigen reduction with immune modulation and standard antivirals.
Opportunities
Risk Factors
Competitive Landscape
The HBV cure landscape is competitive, with major players like Gilead, Janssen/Arrowhead, and GSK advancing combination therapies. Arbutus differentiates through its dedicated focus on a multi-mechanistic 'Suppress, Reduce, Boost' paradigm and a leadership team with strong transactional expertise to navigate partnerships.